Literature DB >> 17043013

JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia.

Konstanze Döhner, Juan Du, Andrea Corbacioglu, Claudia Scholl, Richard F Schlenk, Hartmut Döhner.   

Abstract

Significant progress has been made in identifying genetic lesions that are causally implicated in the pathogenesis of acute myeloid leukemia (AML). These insights improve our understanding of the genetic basis of the disease, a prerequisite for the development of novel therapeutic approaches.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17043013

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  10 in total

1.  AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.

Authors:  X N Gao; F Yan; J Lin; L Gao; X L Lu; S C Wei; N Shen; J X Pang; Q Y Ning; Y Komeno; A L Deng; Y H Xu; J L Shi; Y H Li; D E Zhang; C Nervi; S J Liu; L Yu
Journal:  Leukemia       Date:  2015-03-02       Impact factor: 11.528

2.  A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.

Authors:  Eisaku Iwanaga; Tomoko Nanri; Naofumi Matsuno; Toshiro Kawakita; Hiroaki Mitsuya; Norio Asou
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

3.  Prognostic impact of residual normal metaphases in acute myeloid leukemia with t(8;21)(q22;q22).

Authors:  Lijun Wen; Jing Xia; Qinrong Wang; Hong Yao; Jundan Xie; Jinlan Pan; Yongquan Xue; Depei Wu; Suning Chen
Journal:  Int J Hematol       Date:  2015-06-04       Impact factor: 2.490

Review 4.  Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.

Authors:  Ehab Atallah; Srdan Verstovsek
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

5.  JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.

Authors:  Dong Wook Jekarl; Sang Bong Han; Myungshin Kim; Jihyang Lim; Eun-Jee Oh; Yonggoo Kim; Hee-Je Kim; Woo-Sung Min; Kyungja Han
Journal:  Korean J Hematol       Date:  2010-03-31

6.  Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Authors:  Eleftheria Hatzimichael; Georgios Georgiou; Leonidas Benetatos; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-01-17

Review 7.  Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Clara D Bloomfield
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

8.  Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.

Authors:  Håkon Reikvam; Kimberley Joanne Hatfield; Astrid Olsnes Kittang; Randi Hovland; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2011-05-03

Review 9.  Profile of pacritinib and its potential in the treatment of hematologic disorders.

Authors:  Eleftheria Hatzimichael; Evangelos Tsolas; Evangelos Briasoulis
Journal:  J Blood Med       Date:  2014-08-19

10.  The clinical mutatome of core binding factor leukemia.

Authors:  Sabrina Opatz; Stefanos A Bamopoulos; Klaus H Metzeler; Tobias Herold; Bianka Ksienzyk; Kathrin Bräundl; Sebastian Tschuri; Sebastian Vosberg; Nikola P Konstandin; Christine Wang; Luise Hartmann; Alexander Graf; Stefan Krebs; Helmut Blum; Stephanie Schneider; Christian Thiede; Jan Moritz Middeke; Friedrich Stölzel; Christoph Röllig; Johannes Schetelig; Gerhard Ehninger; Alwin Krämer; Jan Braess; Dennis Görlich; Maria Cristina Sauerland; Wolfgang E Berdel; Bernhard J Wörmann; Wolfgang Hiddemann; Karsten Spiekermann; Stefan K Bohlander; Philipp A Greif
Journal:  Leukemia       Date:  2020-01-02       Impact factor: 11.528
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.